Preclinical evaluation of nutraceuticals’ beneficial effects is a mandatory step to develop such treatments. Physiogenex offers nutraceuticals preclinical studies to evaluate your products targeting obesity, insulin resistance, type 2 diabetes and related metabolic disorders using our benchmarked Diet-Induced Obese (DIO) mouse, rat and hamster models.

Our models have been benchmarked with anti-obesity drugs (e.g. G 5HT2c-receptor agonist lorcaserin), vegetal extracts such as green coffee and green tea extracts, as well as prebiotics (fructo oligosaccharide and polydextrose) and probiotics (e.g. Probiotic B420 Saccharomyces Boulardii).

Our clients benefit from our long experience in handling and evaluating vegetal extracts or pre/probiotics on obesity, insulin resistance, type 2 diabetes, but also MASLD/MASH. Our > 15 years expertise allows us to deliver reliable results and to help our clients reduce the time to market for their newly developed nutraceuticals.

If you focus on gut microbiota, you will also benefit from our partnership with Vaiomer, a pioneer company providing a unique platform to sequence, analyse and quantify gut, oral, blood and tissue microbiota.

Experimental in vivo models for nutraceuticals

Nutritional animal models

Diet-induced obese mouse:

Free-choice diet-induced obese rat:

Free-choice diet-induced obese hamster:


Preclinical CRO services for nutraceuticals

In vivo drug efficacy studies
  • Glucose homeostasis
  • Lipid metabolism
  • Complementary techniques associated to diabetes and insulin resistance
  • Complementary techniques associated to lipid disorders
  • Body composition : EchoMRI
Biochemistry assays and histology
  • Biochemistry/biomarkers
  • Indirect calorimetry
  • Cardiometabolic parameters
  • Basic services: body weight, food intake, lipid homeostasis, blood collection and tissue harvesting